⚡ MARKET RECAP → Major averages post their best day since May as hopes rise of peace in the middle east.

⛽ $4 GAS WON’T SPOOK THE FED → Even as gas prices climb toward $4, the Fed is unlikely to hike rates because energy inflation is supply-driven and can actually slow growth — meaning higher pump prices may ultimately strengthen the case for rate cuts, not tightening.

💊 LILLY BUYS INTO SLEEP DRUGS → Eli Lilly (LLY) is acquiring Centessa to expand into sleep-disorder treatments, using its GLP-1-driven cash flow to build a broader pipeline and tap into a growing, underdeveloped therapeutic market.

Was this email forwarded to you? Sign up for free here.

For the week beginning March 30, 2026

⛽ Gas prices near $4 aren’t enough to trigger rate hikes. Even as rising oil pushes fuel costs higher, the Fed is unlikely to respond with tighter policy because energy-driven inflation is viewed as temporary and supply-driven — not a sign of overheating demand. In other words, higher gas hits consumers, but it doesn’t necessarily change the Fed’s core inflation outlook.

📉 In fact, expensive gas can slow the economy. Higher fuel costs act like a tax on households, reducing discretionary spending and weighing on growth. That dynamic can actually cool the economy — the opposite of what would justify rate hikes — and could reinforce the case for easing if broader demand weakens.

📊 Markets are starting to flip the narrative. Instead of fearing more tightening, investors increasingly see rising energy prices as a drag that could accelerate rate cuts later in 2026. The Fed’s focus remains on underlying inflation trends, not volatile energy spikes, keeping policy anchored to the bigger picture.

💊 Eli Lilly (LLY) is acquiring Centessa to expand into sleep-disorder treatments. The deal brings Centessa’s pipeline — including therapies targeting narcolepsy and other sleep conditions — under Lilly’s umbrella, marking a strategic push beyond its blockbuster diabetes and weight-loss franchises.

🧠 This is a pipeline diversification play. Lilly has dominated headlines with GLP-1 drugs, but the Centessa acquisition signals a broader ambition to build a multi-therapeutic portfolio. Sleep disorders represent a sizable and underpenetrated market, with growing demand for novel treatments that go beyond traditional stimulants.

📊 Investors see long-term optionality. While the deal won’t move near-term earnings, it adds another growth vector to Lilly’s already strong pipeline. The strategy mirrors big pharma’s playbook: use cash flows from dominant drugs to acquire future innovation — especially in areas with unmet medical need and pricing power.

Oracle cutting thousands in latest layoff round as company continues to ramp AI spending (CNBC)

_{^{Investment advisory services provided by ML Wealth LLC. Investment Accounts Are Not FDIC Insured • No Bank Guarantee • Investments May Lose Value. For important information and disclosures relating to the MoneyLion Investment Account, see Investment FAQs, Form ADV Brochure, and moneylion.com/investing. Funded managed investing accounts are subject to a monthly account fee of $1 (for accounts valued up to $5,000), $3 (for accounts valued over $5,000, and up to $25,000), or $5 (for accounts valued over $25,000).}}

<sub><sup>This advertising email was sent to you because you have a MoneyLion account. If you would like to unsubscribe, please do so using this link. We respect your right to privacy. Please do not reply to this email with sensitive information, such as an account number, Social Security number, date of birth, bank account information, PIN, password, or Online ID. The security and confidentiality of your personal information is important to us. If you have any questions or want to read more, please visit our Help Center.

MoneyLion and Pathward do not provide, nor do they guarantee, any third-party product, service, information, or recommendation. The third parties providing these products or services are solely responsible for them, as well as all other content on their websites. MoneyLion is not liable for any third party’s failure with regard to those advertised products, services, and benefits. These advertised products and services may not be FDIC insured or bank-guaranteed, and may be subject to a different privacy policy than MoneyLion’s. You should check individual offers, products, and services to become familiar with any applicable restrictions or conditions that may apply. MoneyLion may receive compensation from third parties for referring you to the third party, their products or to their website.

The influencer, creator and other content provided in the MoneyLion App (“Content”) is for informational and entertainment purposes only and should not be construed as legal, tax, investment, financial, or other advice. All Content is intended to be of a general nature, does not address the circumstances of any particular individual or entity, and may not constitute a comprehensive or complete statement of the matters discussed. MoneyLion is not a fiduciary by virtue of any person’s use of or reliance on the Content. You should consult an appropriate professional if you require any legal, tax, investment, financial or other advice. Terms and Conditions for our subscriber referral can be found here.</sup></sub>